May 23, 2019 - 9:00 AM
May 23, 2019 - 5:00 PM
Assessment of Needs
Rapid advances in HIV disease management require the ongoing attention of practitioners involved in HIV medicine. This course will address the implications of new information on strategies for clinical management. Information will be presented through a mix of didactic lectures and clinically relevant cases developed by an expert faculty of HIV/AIDS clinicians and researchers.
After participating in the activity, learners will be better able to:
- Apply newly available data to antiretroviral strategies for management of established HIV infection
- Identify situations in which antiretroviral regimens should consider particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
- Increase primary prevention through use of preexposure prophylaxis (PrEP) by determining which patients might benefit from PrEP and initiate and monitor use of PrEP for uninfected patients at risk for HIV infection
- Describe the most current data on investigational new drugs and approaches
- Incorporate selected aspects of primary care for individuals with HIV infection, especially in the aging population, which may include:
- Screening for cancer
- Sexually transmitted infections and opportunistic infections screening, treatment, and prevention
- Renal disease
- Cardiovascular disease
- Bone disease
- Endocrine disorders
- Neurocognitive disorders
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”
Who Should Attend
This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:
- Have a solid, working knowledge of HIV disease management
- Provide comprehensive or specialty care for patients with HIV infection
- Are currently active in HIV research
This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.
Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.
Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This activity is eligible for ANCC and pharmacotherapy credits; see final CNE activity announcement for specific details.
This activity is eligible for ACPE credit; see final CPE activity announcement for specific details.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Food and beverages at IAS–USA events are purchased with registration fees, not with grant support money. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc.
Merck & Co, Inc.
Additional support has been provided by
Physician Payment Sunshine Act (“Sunshine Act” or “Open Payment”)
In 2014, the Physician Payment Sunshine Act (“Sunshine Act” or “Open Payments”), a provision of the Affordable Care Act, was developed. According to the Centers for Medicare and Medicaid Services (CMS): “Open Payments is a national disclosure program that promotes transparency by publishing the financial relationships between the medical industry and healthcare providers (physicians and hospitals) on a publicly accessible website developed by CMS.” Until recently, CME activities that receive commercial support have been exempt from reporting payments for goods such as hosted meals. Attendee registration fees are used for all food and beverage expenses provided by IAS–USA at the activity.